Bone loss in adolescents using Depo-Provera.
OBJECTIVE
Contraceptive methods that decrease bone density in a population already deficient in calcium are a rising concern in women's health.


CONCLUSIONS
Use of Depo-Provera (DMPA) significantly decreases bone mass density (BMD) in normal adolescents up to the age of 21. DMPA is often used in adolescents with disabilities who may already be at high risk for osteoporosis. The effects are likely to be similar to that in able-bodied adolescents, but research is limited.


CONCLUSIONS
Through early identification of risk factors in able-bodied and disabled adolescents, primary care providers considering the use of DMPA in adolescents can optimize BMD by providing adequate nutritional assessment, counseling on nutritional sources of calcium, calcium supplementation, guidance on exercise, and alcohol and smoking prevention or cessation.
Kass-Wolff
J H
JH
University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, USA. jwolff1217@aol.com
D000293:Adolescent / Q000502:physiology*; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects*; D003271:Contraceptive Agents, Female / Q000009:adverse effects* / Q000494:pharmacology; D006233:Persons with Disabilities; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects* / Q000494:pharmacology; D009730:Nursing Assessment; D015596:Nutrition Assessment; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D010353:Patient Education as Topic; D018579:Patient Selection; D010371:Pediatric Nursing / Q000379:methods; D011320:Primary Health Care / Q000379:methods; D012307:Risk Factors
D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate